Surgery in reference centers improves survival of sarcoma patients: a nationwide study.
Adolescent
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
France
/ epidemiology
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ mortality
Prognosis
Prospective Studies
Referral and Consultation
/ statistics & numerical data
Registries
Sarcoma
/ mortality
Surgical Procedures, Operative
/ standards
Survival Rate
Young Adult
reference center
relapse
resection
sarcoma
surgery
survival
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
pubmed:
14
5
2019
medline:
24
6
2020
entrez:
14
5
2019
Statut:
ppublish
Résumé
NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and expert pathological review are mandatory for sarcoma patients nationwide. In the present work, the impact of surgery in a reference center on the survival of sarcoma patients investigated using this national NETSARC registry. Patients' characteristics and follow-up are prospectively collected and data monitored. Descriptive, uni- and multivariate analysis of prognostic factors were conducted in the entire series (N = 35 784) and in the subgroup of incident patient population (N = 29 497). Among the 35 784 patients, 155 different histological subtypes were reported. 4310 (11.6%) patients were metastatic at diagnosis. Previous cancer, previous radiotherapy, neurofibromatosis type 1 (NF1), and Li-Fraumeni syndrome were reported in 12.5%, 3.6%, 0.7%, and 0.1% of patients respectively. Among the 29 497 incident patients, 25 851 (87.6%) patients had surgical removal of the sarcoma, including 9949 (33.7%) operated in a NETSARC center. Location, grade, age, size, depth, histotypes, gender, NF1, and surgery outside a NETSARC center all correlated to overall survival (OS), local relapse free survival (LRFS), and event-free survival (EFS) in the incident patient population. NF1 history was one of the strongest adverse prognostic factors for LRFS, EFS, and OS. Presentation to an MDTB was associated with an improved LRFS and EFS, but was an adverse prognostic factor for OS if surgery was not carried out in a reference center. In multivariate analysis, surgery in a NETSARC center was positively correlated with LRFS, EFS, and OS [P < 0.001 for all, with a hazard ratio of 0.681 (95% CI 0.618-0.749) for OS]. This nationwide registry of sarcoma patients shows that surgical treatment in a reference center reduces the risk of relapse and death.
Sections du résumé
BACKGROUND
NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and expert pathological review are mandatory for sarcoma patients nationwide. In the present work, the impact of surgery in a reference center on the survival of sarcoma patients investigated using this national NETSARC registry.
PATIENTS AND METHODS
Patients' characteristics and follow-up are prospectively collected and data monitored. Descriptive, uni- and multivariate analysis of prognostic factors were conducted in the entire series (N = 35 784) and in the subgroup of incident patient population (N = 29 497).
RESULTS
Among the 35 784 patients, 155 different histological subtypes were reported. 4310 (11.6%) patients were metastatic at diagnosis. Previous cancer, previous radiotherapy, neurofibromatosis type 1 (NF1), and Li-Fraumeni syndrome were reported in 12.5%, 3.6%, 0.7%, and 0.1% of patients respectively. Among the 29 497 incident patients, 25 851 (87.6%) patients had surgical removal of the sarcoma, including 9949 (33.7%) operated in a NETSARC center. Location, grade, age, size, depth, histotypes, gender, NF1, and surgery outside a NETSARC center all correlated to overall survival (OS), local relapse free survival (LRFS), and event-free survival (EFS) in the incident patient population. NF1 history was one of the strongest adverse prognostic factors for LRFS, EFS, and OS. Presentation to an MDTB was associated with an improved LRFS and EFS, but was an adverse prognostic factor for OS if surgery was not carried out in a reference center. In multivariate analysis, surgery in a NETSARC center was positively correlated with LRFS, EFS, and OS [P < 0.001 for all, with a hazard ratio of 0.681 (95% CI 0.618-0.749) for OS].
CONCLUSION
This nationwide registry of sarcoma patients shows that surgical treatment in a reference center reduces the risk of relapse and death.
Identifiants
pubmed: 31081028
pii: S0923-7534(19)31232-3
doi: 10.1093/annonc/mdz124
pmc: PMC6637376
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1153Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Références
J Orthop Sci. 2015 Mar;20(2):373-9
pubmed: 25613392
Arch Orthop Trauma Surg. 2000;120(1-2):65-9
pubmed: 10653107
BMC Health Serv Res. 2012 Mar 28;12:82
pubmed: 22455759
Sarcoma. 2018 Apr 3;2018:8141056
pubmed: 29849479
Ann Oncol. 2017 Oct 1;28(10):2399-2408
pubmed: 28961825
J Natl Compr Canc Netw. 2016 Jun;14(6):758-86
pubmed: 27283169
Eur J Surg Oncol. 2006 Dec;32(10):1242-8
pubmed: 16793237
Adv Exp Med Biol. 2010;686:285-303
pubmed: 20824452
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95
pubmed: 30285218
Oncologist. 2019 Jun;24(6):e338-e346
pubmed: 30409793
PLoS One. 2011;6(8):e20294
pubmed: 21826194
Int J Clin Oncol. 2014 Aug;19(4):744-52
pubmed: 23933822
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78
pubmed: 29846513
Value Health. 2014 Nov;17(7):A624
pubmed: 27202203
Ann Surg. 2002 Mar;235(3):424-34
pubmed: 11882765
Clin Sarcoma Res. 2016 Nov 15;6:20
pubmed: 27891213
Cancer Med. 2016 Jun;5(6):980-8
pubmed: 26929181
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
J Clin Oncol. 2005 Jan 1;23(1):96-104
pubmed: 15625364
J Bone Joint Surg Am. 1996 May;78(5):650-5
pubmed: 8642020
Lancet Oncol. 2016 Feb;17(2):e62-e69
pubmed: 26868355
Eur J Surg Oncol. 2019 Jan;45(1):31-39
pubmed: 28985973
Curr Opin Oncol. 2017 Jul;29(4):268-274
pubmed: 28489620
Ann Oncol. 2017 Nov 1;28(11):2852-2859
pubmed: 29117335
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473
Acta Orthop Suppl. 2009 Apr;80(334):1-104
pubmed: 19919379
J Bone Joint Surg Br. 2008 Feb;90(2):203-8
pubmed: 18256089
BMC Public Health. 2010 Apr 12;10:188
pubmed: 20384990
Ann Surg Oncol. 2017 Oct;24(11):3279-3288
pubmed: 28748443